Skip to content
RDL
Network
Ekosistem
Uygulama değiştir
EN
Hakkımızda
SSS
Giriş yap
Başla
Rethinking placebos: embracing synthetic control arms in clinical trials for rare tumors — César Serrano (2023) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Rethinking placebos: embracing synthetic control arms in clinical trials for rare tumors
Shared by
Jean Yves Blay
Rethinking placebos: embracing synthetic control arms in clinical trials for rare tumors
Article
2023
en
Authors
+12 more
CS
César Serrano
SR
Sara Rothschild
GV
Guillermo Villacampa
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Article
2017
Clinical trial research in focus: rethinking trials in sepsis
David Grimaldi
,
Jean Louis Vincent
Article
2024
Rare disease clinical trials: challenges and best practices
Giuseppe Remuzzi
Article
2020
Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: Recent advances and clinical trials
Seyed Samad Hosseini
,
Saeed Khalili
,
Behzad Baradaran
,
Negar Bidar
,
Mohammad‐Ali Shahbazi
,
Jafar Mosafer
,
Mahmoud Hashemzaei
,
Ahad Mokhtarzadeh
,
Michael R Hamblin
Article
2008
Challenges in meta-analysis of randomized clinical trials for rare harmful cardiovascular events: The case of rosiglitazone
Adrían V. Hernández
,
Esteban Walker
,
John P A Ioannidis
,
Michael W. Kattan
Article
2002
Fuzzy (PI+D)/sup 2/ control for flexible robot arms
Pitikhate Sooraksa
,
Guanrong Chen
Discussion(0)
No comments yet. Be the first to comment.